Resultados de Búsqueda
Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Current treatment for untreated locally advanced or metastatic urothelial carcinoma when cisplatin-containing chemotherapy is unsuitable is carboplatin plus gemcitabine. Atezolizumab is also an option, but only within the Cancer Drugs Fund, because of uncertainty about its clinical effectiveness. Pembrolizumab has been studied in a single-arm clinical trial (KEYNOTE‑052). It appears to be effective but it's difficult to establish the size of the clinical benefit because it has not been ...
ver más ... 2018Pembrolizumab is recommended as an option for untreated PD‑L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD‑L1 (with at least a 50% tumour proportion ...
NICE
National Institute for Health and Clinical Excellence (NICE)
People with untreated metastatic PD‑L1-positive NSCLC are usually offered platinum-based chemotherapy (docetaxel, gemcitabine, paclitaxel, vinorelbine or pemetrexed, with a platinum-based drug). Clinical trial evidence shows that pembrolizumab increases the length of time people live by nearly 16 months compared with chemotherapy. Although there is uncertainty about the long-term treatment benefit of pembrolizumab after treatment is stopped, there was sufficient evidence of an important ...
ver más ... 2018Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless MRI is contraindicated.
NICE
National Institute for Health and Clinical Excellence (NICE)
The evidence indicated that standard structural MRI is useful in distinguishing high-grade from low-grade glioma. The committee noted that this knowledge will inform management. Based on their experience, the committee recommended a protocol that they defined as a minimum standard for imaging acquisition. No evidence was found on more advanced MRI techniques. However, the committee agreed that in their experience such techniques can be useful for assessing malignant features of a tumour – in ...
ver más ... 2018Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy.
NICE
National Institute for Health and Clinical Excellence (NICE)
Treatment options for people with locally advanced unresectable or metastatic urothelial carcinoma who have had platinum-containing therapy are limited. They are usually offered docetaxel, paclitaxel and best supportive care. Nivolumab has been studied in a clinical trial, but it has not been directly compared with other treatments. So it is not clear how effective nivolumab is compared with current clinical practice. Nivolumab meets NICE's criteria to be considered a life-extending treatment ...
ver más ... 2018Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
NICE
National Institute for Health and Clinical Excellence (NICE)
These recommendations only cover people with locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy. There is separate guidance on atezolizumab for untreated disease for people who cannot have cisplatin. Treatment options for people whose disease has progressed after platinum-containing chemotherapy include docetaxel, paclitaxel or best supportive care. Evidence from 2 clinical trials, one of which compares atezolizumab directly with chemotherapy, ...
ver más ... 2018